Lixte Biotechnology Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Lixte Biotechnology Holdings has a total shareholder equity of $1.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.7M and $329.0K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.64m |
| Equity | US$1.37m |
| Total liabilities | US$328.96k |
| Total assets | US$1.70m |
Recent financial health updates
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 08
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
May 05Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Jan 20We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
Jul 20Recent updates
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 08Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
May 05Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Jan 20We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
Jul 20Lixte Biotechnology starts enrollment in early-stage lung cancer study
Jun 02Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 25Financial Position Analysis
Short Term Liabilities: LIXT's short term assets ($1.7M) exceed its short term liabilities ($329.0K).
Long Term Liabilities: LIXT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LIXT is debt free.
Reducing Debt: LIXT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LIXT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LIXT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.5% each year